Types of Dermatomyositis
Dermatomyositis is classified into several distinct subtypes based on the 2017 EULAR/ACR criteria: classic dermatomyositis (DM), juvenile dermatomyositis (JDM), amyopathic dermatomyositis (ADM), and hypomyopathic DM, with further phenotypic differentiation based on myositis-specific autoantibodies. 1
Major Classification Framework
The 2017 EULAR/ACR guidelines establish a hierarchical classification system where patients must first meet criteria for idiopathic inflammatory myopathy (probability ≥55%), then undergo subclassification 1:
Primary Dermatomyositis Subtypes:
Classic Dermatomyositis (DM): Characteristic skin manifestations with clinically evident muscle weakness and inflammation
Juvenile Dermatomyositis (JDM): Onset before age 18, representing 25.5% of inflammatory myopathy cases in the classification cohort 1
Amyopathic Dermatomyositis (ADM): Pathognomonic skin changes with no clinical evidence of muscle disease for ≥6 months after skin manifestations appear 2
Hypomyopathic Dermatomyositis: Hallmark skin changes with no clinical muscle symptoms but subclinical myositis detected on electrophysiology, muscle biopsy, or MRI 2
Post-myopathic DM: Patients whose muscle disease has resolved but skin manifestations persist 3
DM sine dermatitis: Muscle involvement without skin manifestations (rare variant) 3
Autoantibody-Defined Phenotypes
Modern classification increasingly relies on myositis-specific autoantibodies (MSAs), which define distinct clinical phenotypes with different prognoses and organ involvement patterns 4, 5:
Key Autoantibody Associations:
- Anti-Mi2: Classic DM presentation, generally favorable prognosis
- Anti-MDA5: High risk of rapidly progressive interstitial lung disease (ILD), particularly in Asian populations
- Anti-TIF1-γ: Strong association with malignancy in adults (cancer-associated DM)
- Anti-NXP2: Malignancy risk in adults; calcinosis and severe disease in children
- Anti-SAE: Dysphagia and skin-predominant disease
These antibody profiles correlate with distinct cutaneous manifestations, systemic complications, and malignancy risk, making them essential for risk stratification 4.
Clinical Differentiation Strategy
When evaluating a patient with suspected dermatomyositis:
Identify pathognomonic skin lesions: Gottron's papules, Gottron's sign, heliotrope rash with nailfold capillary changes 6
Assess muscle involvement clinically: Symmetric proximal weakness, elevated muscle enzymes (CK, aldolase)
If skin lesions present without clinical myositis: Distinguish ADM (truly no muscle involvement for ≥6 months) from hypomyopathic DM using:
- Muscle MRI for subclinical inflammation
- EMG for electrical abnormalities
- Consider muscle biopsy with MxA immunohistochemistry 6
Order myositis-specific antibodies: This determines phenotype, guides screening for ILD and malignancy, and informs prognosis 4, 5
Age-based classification: Onset <18 years = JDM; ≥18 years = adult DM subtypes 1
Critical Clinical Pitfalls
The absence of muscle weakness does not exclude dermatomyositis—ADM and hypomyopathic variants can have severe systemic complications including ILD and malignancy without myositis 2. The distinction between ADM and hypomyopathic DM requires active investigation with imaging or biopsy, not just clinical observation.
Malignancy-associated DM occurs in approximately 30% of adult cases, with higher risk in elderly patients, males, and those with anti-TIF1-γ or anti-NXP2 antibodies 3. Risk-stratified cancer screening is essential based on antibody profile and age 6.
Anti-MDA5 positive patients require urgent evaluation for rapidly progressive ILD, which can be life-threatening and may occur even in amyopathic disease 7, 6.
The classification tree approach ensures systematic subtyping: first confirm IIM diagnosis (score ≥5.5 without biopsy or ≥6.7 with biopsy), then apply age, antibody, and clinical criteria to assign the specific DM subtype 1.